This site is intended for healthcare professionals

New data from HGB-206 study show near elimination of sickle cell disease-related vaso-occlusive crises by LentiGlobin gene therapy and plans to file at FDA in 2021 .- bluebird bio.

Read time: 4 mins
Last updated:15th Jun 2020
Published:13th Jun 2020
Condition: Sickle Cell Disease
Type: drug
Register free for full access to